OpenAI has acquired Orchestra Bio, a four-year-old AI-powered biotechnology software startup.
OpenAI has acquired Orchestra Bio, a four-year-old AI-powered biotechnology software startup.
The company’s team and technology will join OpenAI’s Rosalind platform, combining AI agents with tools that coordinate complex drug development workflows. The acquisition aims to accelerate scientific research and help bring new treatments to patients sooner.